专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20020114784A1 Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA 审中-公开
标题翻译：使用双链RNA的体内和体外减少基因表达的组合物和方法
公开(公告)号：US20020114784A1
公开(公告)日：2002-08-22
申请号：US10038984
申请日：2002-01-04
申请人： Medical College of Georgia Research Institute, Inc.
发明人： Yin-Xiong Li , Michael J. Farrell , Margaret L. Kirby
IPC分类号： A61K048/00 , C12N015/86
CPC分类号： C12N15/113 , A61K48/0066 , C12N15/63 , C12N2310/13 , C12N2310/14
摘要： Introduction of double stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression.
摘要翻译：将双链RNA引入细胞，细胞培养物，器官和组织以及整个生物体，特别是脊椎动物，特异性地减弱基因表达。

22. 发明申请

US20020155104A1 Regulation of T cell-mediated immunity by tryptophan 有权
标题翻译：调节T细胞介导的色氨酸免疫
公开(公告)号：US20020155104A1
公开(公告)日：2002-10-24
申请号：US10112362
申请日：2002-03-28
申请人： Medical College of Georgia Research Institute, Inc.
发明人： David Munn , Andrew Mellor
IPC分类号： A61K039/395 , A61K039/00 , A61K031/405
CPC分类号： C07K14/47 , A01K67/0271 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K31/405 , A61K38/00 , A61K39/00 , A61K45/06 , A61K48/00 , A61K31/48 , A61K31/44 , A61K31/38 , A61K31/34 , A61K2300/00
摘要： A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby , decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes. Regulation can be further manipulated using cytokines such as macrophage colony stimulating factor, interferon gamma, alone or in combination with antigen or other cytokines.
摘要翻译：巨噬细胞诱导的T细胞抑制的机制是局部巨噬细胞微环境中色氨酸的选择性消除和/或一种或多种色氨酸代谢物的增加。研究证明，IDO的表达可以作为抑制T细胞活化的标志物，并且可能在同种异体妊娠和其他类型的移植中起重要作用，IDO抑制剂可用于激活T细胞，因此当T细胞被妊娠，恶性肿瘤或HIV病毒抑制时，T细胞活化增强。因此，除了或替代IDO抑制剂之外，抑制色氨酸降解（从而增加色氨酸浓度同时降低色氨酸代谢物浓度）或补充色氨酸浓度。类似地，例如通过增加IDO浓度或IDO活性来增加色氨酸降解（从而降低色氨酸浓度和增加色氨酸代谢物浓度）可以抑制T细胞。虽然特别参照IDO调节进行了描述，但是可以改变操作局部色氨酸浓度和/或调节高亲和力色氨酸转运蛋白的活性和/或施用其它色氨酸降解酶。可以使用细胞因子如巨噬细胞集落刺激因子，干扰素γ单独或与抗原或其他细胞因子组合进一步操纵调节。

23. 发明申请

US20010001040A1 Regulation of T cell-mediated immunity by tryptophan 有权
标题翻译：调节T细胞介导的色氨酸免疫
公开(公告)号：US20010001040A1
公开(公告)日：2001-05-10
申请号：US09727055
申请日：2000-11-30
申请人： Medical College of Georgia Research Institute, Inc.
发明人： David Munn , Andrew Mellor
IPC分类号： A61K031/40 , A01N043/38
CPC分类号： C07K14/47 , A01K67/0271 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K31/405 , A61K38/00 , A61K39/00 , A61K45/06 , A61K48/00 , A61K31/48 , A61K31/44 , A61K31/38 , A61K31/34 , A61K2300/00
摘要： A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes. Regulation can be further manipulated using cytokines such as macrophage colony stimulating factor, interferon gamma, alone or in combination with antigen or other cytokines.
摘要翻译：巨噬细胞诱导的T细胞抑制的机制是局部巨噬细胞微环境中色氨酸的选择性消除和/或一种或多种色氨酸代谢物的增加研究证明，IDO的表达可以作为T细胞活化抑制的标志物，并且可能在同种异体妊娠和其他类型的移植中起重要作用，IDO抑制剂可用于激活T细胞，因此当T细胞被妊娠，恶性肿瘤或HIV病毒抑制时，T细胞活化增强。因此，除了或替代IDO抑制剂之外，抑制色氨酸降解（从而增加色氨酸浓度同时降低色氨酸代谢物浓度）或补充色氨酸浓度。类似地，例如通过增加IDO浓度或IDO活性来增加色氨酸降解（从而降低色氨酸浓度和增加色氨酸代谢物浓度）可以抑制T细胞。虽然特别参照IDO调节进行了描述，但是可以改变操作局部色氨酸浓度和/或调节高亲和力色氨酸转运蛋白的活性和/或施用其它色氨酸降解酶。可以使用细胞因子如巨噬细胞集落刺激因子，干扰素γ单独或与抗原或其他细胞因子组合进一步操纵调节。

24. 发明申请

WO2011008939A2 POROUS-WALL HOLLOW GLASS MICROSPHERES AS CARRIERS FOR BIOMOLECULES 审中-公开
标题翻译：多孔玻璃微珠作为生物分子的载体
公开(公告)号：WO2011008939A2
公开(公告)日：2011-01-20
申请号：PCT/US2010/042117
申请日：2010-07-15
申请人： MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. , SAVANNAH RIVER NUCLEAR SOLUTIONS, LLC , LI, Shuyi , DYNAN, William, S. , WICKS, George , SERKIZ, Steven
发明人： LI, Shuyi , DYNAN, William, S. , WICKS, George , SERKIZ, Steven
IPC分类号： A61K9/50
CPC分类号： A61K9/50 , A61K9/0019 , A61K9/501 , A61K9/5036 , A61K31/721 , A61K51/1286
摘要： The present invention includes compositions of porous-wall hollow glass microspheres and one or more biomolecules, wherein the one or more biomolecules are positioned within a void location within the hollow glass microsphere, and the use of such compositions for the diagnostic and/or therapeutic delivery of biomolecules.
摘要翻译：本发明包括多孔壁中空玻璃微球和一种或多种生物分子的组合物，其中所述一种或多种生物分子位于中空玻璃微球内的空隙位置内，以及使用这种组合物进行诊断和/或治疗递送的生物分子。

25. 发明申请

WO2010151638A1 JNK INHIBITORS FOR USE IN TREATING SPINAL MUSCULAR ATROPHY 审中-公开
标题翻译： JNK抑制剂用于治疗脊髓性肌阵挛
公开(公告)号：WO2010151638A1
公开(公告)日：2010-12-29
申请号：PCT/US2010/039779
申请日：2010-06-24
申请人： MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. , GANGWANI, Laxman
发明人： GANGWANI, Laxman
IPC分类号： A61K38/17 , A61K31/00 , A61K48/00 , A61P25/00
CPC分类号： A61K38/1709 , A61K31/416 , C12N15/113 , C12N2310/14
摘要： The brain specific isoform (JNK3) of c-Jun NH2-terminal kinase (JNK) has been found to mediate the degeneration of spinal motor neurons caused by SMN deficiency in spinal muscular atrophy (SMA). Moreover, the ability of JNK inhibitors to reduce degeneration of neurons lacking SMN is also disclosed. The JNK signaling pathway can therefore mediate neurodegeneration in SMA and represents a therapeutic target for treatment of SMA.
摘要翻译：已经发现c-Jun NH2-末端激酶（JNK）的脑特异性同种型（JNK3）介导由脊髓性肌萎缩（SMA）中的SMN缺陷引起的脊髓运动神经元的退化。此外，还公开了JNK抑制剂减少缺乏SMN的神经元变性的能力。因此，JNK信号通路可以介导SMA中的神经退行性疾病，代表治疗SMA的治疗靶点。

26. 发明申请

WO2010080962A2 HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCER 审中-公开
标题翻译：作为脑病和癌症的模型系统的热休克蛋白缺陷
公开(公告)号：WO2010080962A2
公开(公告)日：2010-07-15
申请号：PCT/US2010/020446
申请日：2010-01-08
申请人： MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. , MIVECHI, Nahid, F. , EROGLU, Binnur , MOSKOFIDIS, Dimitrios
发明人： MIVECHI, Nahid, F. , EROGLU, Binnur , MOSKOFIDIS, Dimitrios
IPC分类号： A01K67/027 , C12N15/12 , C12N5/10 , G01N33/15
CPC分类号： C07K14/4711 , A01K67/0276 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/0312 , A01K2267/0318 , A01K2267/0331 , A01K2267/0356 , A01K2267/0393 , C12N15/8509
摘要： The invention provides non-human transgenic animals as models of neurodegenerative brain pathology, including, but not limited to, Alzheimer's disease (AD), and cancer. The non-human transgenic animals of the present invention include an exogenous DNA that reduces or eliminates the expression and/or function of a molecular chaperone, including, but not limited to heat shock protein 110 (Hspl 10) or heat shock protein 70 (Hsp70). These non-human transgenic animals may be used in methods of screening and identifying compounds useful for the prevention and/or treatment of neurodegenerative brain pathology and/or cancer.
摘要翻译：本发明提供非人转基因动物作为神经变性脑病理学模型，包括但不限于阿尔茨海默氏病（AD）和癌症。本发明的非人转基因动物包括减少或消除分子伴侣的表达和/或功能的外源DNA，包括但不限于热休克蛋白110（Hspl10）或热休克蛋白70（Hsp70 ）。这些非人转基因动物可用于筛选和鉴定可用于预防和/或治疗神经变性脑病理学和/或癌症的化合物的方法。

27. 发明申请

WO2010042685A2 INHIBITORS OF THE ATB(0,+) TRANSPORTER AND USES THEREOF 审中-公开
标题翻译： ATB（0，+）输送器的抑制剂及其用途
公开(公告)号：WO2010042685A2
公开(公告)日：2010-04-15
申请号：PCT/US2009/059946
申请日：2009-10-08
申请人： MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. , GANAPATHY, Vadivel , THANGARAJU, Muthusamy , PRASAD, Puttur
发明人： GANAPATHY, Vadivel , THANGARAJU, Muthusamy , PRASAD, Puttur
IPC分类号： A61K31/405 , A61P35/00
CPC分类号： A61K39/3955 , A61K31/00 , A61K31/405 , A61K45/06
摘要： The present invention includes inhibitors of the amino acid transporter ATB 0,+ and methods of uses thereof.
摘要翻译：本发明包括氨基酸转运蛋白ATB 0，+的抑制剂及其使用方法。

28. 发明申请

WO2009092017A1 BIOMARKERS FOR HPV-INDUCED CANCER 审中-公开
标题翻译： HPV感染癌的生物标志物
公开(公告)号：WO2009092017A1
公开(公告)日：2009-07-23
申请号：PCT/US2009/031302
申请日：2009-01-16
申请人： MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. , DYNAN, William , ARNOUK, Hilal , MERKLEY, Mark , LEE, Jeffrey , FERRIS, Daron , STOPPLER, Hubert , PODOLSKY, Robert, H.
发明人： DYNAN, William , ARNOUK, Hilal , MERKLEY, Mark , LEE, Jeffrey , FERRIS, Daron , STOPPLER, Hubert , PODOLSKY, Robert, H.
IPC分类号： C12Q1/00 , G01N33/48
CPC分类号： G01N33/57411
摘要： Biomarkers that correlate with progression to neoplasia in human papillomavirus (HPV) induced cancer, for example cervical cancer have been identified. These biomarkers can be used to diagnosis or assist in the diagnosis of HPV-induced cancer. They can also be used to increase the positive predictive value of current screening modalities. In addition, they can provide insights into the biology of HPV-induced cancer and thus provide leads for the development of nonsurgical therapies. Exemplary biomarkers include cornulin, PA28 β, DJ-l, actin, transthyretin, HSPB1, CV intracellular channel 1, cytokeratin 8, transferrin, Hsρβ6 (HSP20), aflatoxin reductase, α2 type I collagen, creatine kinase B, cytokeratin 13 GST π, PA28 α, Manganese SOD, lamin A/C, serpin B1 (elastase inhibitor), serpin B3 (SCAA1), cytokeratin 10, cytokeratin 6A, and trp-tRNA synthetase. Preferred biomarkers for HPV-induced cancer include cornulin, DJ-l, PA28 α, and PA28 β, trp-tRNA synthetase, HSPβ6, creatine kinase B, aflatoxin reductase, GST π, transthyretin, transferrin, α2-type 1 collagen, and combinations thereof.
摘要翻译：与人乳头状瘤病毒（HPV）诱导的癌症（例如宫颈癌）发展相关的生物标志物已被鉴定。这些生物标志物可用于诊断或协助HPV诱导的癌症的诊断。它们也可用于增加当前筛选模式的阳性预测值。此外，他们可以深入了解HPV诱导的癌症的生物学，从而为非手术疗法的发展提供依据。示例性生物标志物包括cornulin，PA28β，DJ-1，肌动蛋白，转甲状腺素蛋白，HSPB1，CV细胞内通道1，细胞角蛋白8，转铁蛋白，Hsβ6（HSP20），黄曲霉毒素还原酶，a2型I胶原，肌酸激酶B，细胞角蛋白13 GST p，PA28a，锰SOD，lamin A / C，丝氨酸蛋白酶B1（弹性蛋白酶抑制剂），丝氨酸蛋白酶B3（SCAA1），细胞角蛋白10，细胞角蛋白6A和trp-tRNA合成酶。用于HPV诱导的癌症的优选生物标志物包括cornulin，DJ-1，PA28a和PA28β，trp-tRNA合成酶，HSPβ6，肌酸激酶B，黄曲霉毒素还原酶，GST p，转甲状腺素蛋白，转铁蛋白，a2-型1胶原和组合它们。

29. 发明申请

WO2009059289A2 NETRIN-1 COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
标题翻译： NETRIN-1组合物及其使用方法
公开(公告)号：WO2009059289A2
公开(公告)日：2009-05-07
申请号：PCT/US2008/082238
申请日：2008-11-03
申请人： MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. , XIONG, Wen-Cheng , LEE, Jae-Ho , MEI, Lin
发明人： XIONG, Wen-Cheng , LEE, Jae-Ho , MEI, Lin
IPC分类号： A61K38/17
CPC分类号： A61K38/18 , G01N33/689 , G01N2333/475 , G01N2800/367
摘要： Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.
摘要翻译：提供了用于男性或女性避孕的方法和组合物。所述组合物包含有效量的netrin-1以降低或抑制雄性精液中的精子浓度，或抑制或减少雄性配子与女性配子中的雌性配子的融合。又一实施方式提供了通过确定雌性个体中的雌性配子 netrin-1在男性受试者的附睾液或精液样品中的浓度，将样品中的结网-1的量与附睾液或来自可育雄性的精液的样品中的netrin-1的水平进行比较，其中netrin-1 在来自男性受试者的样品中，其来自可育雄性样品中高于或低于netrin-1水平的样品指示男性受试者中的男性不育症。

30. 发明申请

WO2007087292A3 MAPC TREATMENT OF BRAIN INJURIES AND DISEASES 审中-公开
公开(公告)号：WO2007087292A3
公开(公告)日：2007-08-02
申请号：PCT/US2007/001746
申请日：2007-01-23
申请人： ATHERSYS, INC. , MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. , MAYS, Robert W. , DEANS, Robert J. , HESS, David C. , CARROLL, James E. , BORLONGAN, Cesar V.
发明人： MAYS, Robert W. , DEANS, Robert J. , HESS, David C. , CARROLL, James E. , BORLONGAN, Cesar V.
IPC分类号： A61K35/50 , A61P9/10
摘要： The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式